New York, USA – June 1, 2022 – Creative Bioarray specializes in standard and custom in vitro assays, providing customers with cost-effective, high-quality, reproducible data and flexible solutions with fast turnaround times. The professional team is dedicated to helping customers accelerate life science research, solve complex analytical challenges and increase laboratory productivity. Recently, Creative Bioarray announces the release of its transporter screening services to identify transporter targeting compounds and accelerate drug research.
Creative Bioarray offers specialized transporter panels and custom transporter screening services that enable customers to identify novel transporter-targeting compounds. Available transporter panels include FDA transporter screening panels, monoamine transporter models, and many other cellular models. Creative Bioarray employs robust transporter uptake and inhibition assays to screen new molecular entities (NMEs) quickly and efficiently and provides customers with results with good signal-to-background ratios and Z-scores.
Creative Bioarray provides clinically important transporter targets such as ATP-binding cassette transporter (P-gp), neurotransmitter (SERT, DAT, NET) and solution carrier family transporter (SLC13). Detection methods include radioisotope detection, fluorescence detection and ion flux detection. During the drug discovery process, understanding potential compound interactions with transporters in the early stages of development is critical for selecting drug candidates with desirable drug metabolism and safety profile. Creative Bioarray offers a wide range of transport and penetration testing services, state-of-the-art equipment, and scientific expertise in DMPK to support specific needs.
Creative Bioarray’s drug transporter can test compound interactions – with ABC and SLC transporters (P-gp, BCRP, MRP2, BSEP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, MATE2-K, etc.), providing high-quality data – tested at a single concentration or multiple concentrations to generate IC50 values and following regulatory guidelines – use regulatory agency-recommended probe substrates, inhibitors, and test parameters.
“We a variety of panels for screening and analysis of transporter compounds. Our experienced and talented scientists are dedicated to helping you identify the compounds most likely to succeed.” said Hannah Cole, the marketing director of Creative Bioarray, she also claimed, “We are confident to accelerate your drug discovery project and provide you with fast turnaround times and high-quality results.”
About DDA platform
As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.